Calliditas Therapeutics

Dealing with a disease like IgA nephropathy (#IgAN) can be a lot, as it can impact patients physically and emotionally. Finding credible resources is critical to supporting patients with IgAN. Explore IgAN Connect now: https://lnkd.in/eYp9aRTH

Our CEO will be speaking at the upcoming #Biotech CEO Summit sponsored by Demy-Colton. We look forward to her thoughts around achieving approval across geographies and the journey to creating a successful, sustainable #RareDisease company. Learn more: https://lnkd.in/guPXxpzh

Our partnerships with organizations like the National Kidney Foundation and The IgA Nephropathy Foundation help us connect to the patient community. We are proud to sponsor a joint initiative between these partners called “Improving Quality Care for Patients Living with IgAN.” This will help us identify barriers and solutions to optimal communications during office visits. We’re excited to be part of this initiative.

Our partner Viatris Pharmaceuticals Japan Inc. has launched a Phase 3 clinical trial of our treatment for IgA nephropathy in Japan. This milestone brings us closer to potentially providing a much-needed treatment option for patients in Japan who currently have limited treatment options this rare disease. Learn more: https://bit.ly/3RXed1E

We are grateful to be sponsoring the 2024 SPARK Conference alongside The IgA Nephropathy Foundation. #IgANSpark24 emphasizes the importance of connecting and supporting patients with IgAN. Learn more: https://iganspark.org/

Thierry Christophe, VP of Research, is a wonderful part of our #CalliditasCommunity! He epitomizes our core values and helps to advance our pipeline. His spirit and dedication to preclinical research are what elevate our team to such a high standard. Thank you, Thierry, for all you do!

The potential use of biomarkers for the care of IgA nephropathy (IgAN) is emerging. Learn more as faculty of our educational resource IgANexus, Dr. Jonathan Barratt and Dr. Dana Rizk, discuss the role of biomarkers in clinical practice for #IgAN: https://lnkd.in/gRE64scN

Setanaxib, the first drug candidate to reach the clinic from the NOX platform, is designed to specifically reduce reactive oxygen species, which is implicated in fibrosis and inflammation pathways. Learn more about its potential for fibrotic diseases: https://lnkd.in/g-JA7BKp

The FDA approval of our treatment for IgA nephropathy (IgAN) established the first and only approved treatment to reduce the loss of kidney function in adults with #IgAN. This approach has the potential to become a cornerstone treatment option. https://lnkd.in/gZVBdzyT

The United States Patent and Trademark Office (USPTO) has issued a patent for the product protection of our candidate, setanaxib. The patent covers a method of treating a solid tumor by administering setanaxib in combination with a PD-1 inhibitor, expiring in 2039. We look forward to expanding to other geographies with this patent protection in oncology. Learn more: https://lnkd.in/ghFiFDSi